Myopia ProgressingNCT06884527
Myopia Control With a Innovative Spectacle Lens - A Cessation Study
A study testing Single Vision Lens to A innovative spectacle lens in people with Myopia Progressing, run by Essilor International at 5 sites in United States.
Trial summary
The purpose of this study is to quantify myopic progression following cessation of a innovative spectacle lenses after 3 years' use. Read more about this study
- Who is it for?
- Ages 9 to 15 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia Progressing
- What is being tested?
- Single Vision Lens to A innovative spectacle lens
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 91 participants
- Where
- 5 sitesUnited States
- Study dates
- 18 Feb 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 15 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Existing subjects from the NCT05174780 clinical study.
- Ability to comply with study procedures.
- Informed consent of parent/guardian and assent of subject.
Who cannot join
- Current ocular infection, inflammation, or irritation likely to affect vision.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
New England College of Optometry
Boston, Massachusetts, 02115
Illinois College of Optometry
Chicago, Illinois, 60616
SUNY College of Optometry
New York, New York, 10036
Kannarr Eye Care
Pittsburg, Kansas, 66762
Sacco Eye Group
Vestal, New York, 13850
About this study
Official title: Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression - A Cessation Study
The purpose of this study is to quantify myopic progression following cessation of a innovative spectacle lenses after 3 years' use.
- Conditions
- Myopia Progressing
- Being tested
- Single Vision Lens to A innovative spectacle lens
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single Vision Lens to A innovative spectacle lensDevice
Participants in this arm are from the test group of the previous clinical trial (NCT05174780), where they wore the innovative spectacle lenses for three years. They will now wear single vision lenses for 12 months.
Single Vision Lens to A innovative spectacle lensDevice
Participants in this arm are from the control group of the previous clinical trial (NCT05174780), where they wore the single vision spectacle lenses for three years. They will now wear single vision lenses for another 12 months.
| Study group | Role | What they receive |
|---|---|---|
| (Previous Test Group) - Single Vision Spectacle Lens - Innovative Lens | Experimental | Not described Receives: Device: Single Vision Lens to A innovative spectacle lens |
| (Previous Control Group) - Single Vision Spectacle Lens - Innovative Lens | Placebo comparator | Not described Receives: Device: Single Vision Lens to A innovative spectacle lens |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in cycloplegic spherical equivalent refraction from baseline
Measured: 0 - 12 months
Change in Axial Length from baseline
Measured: 0 - 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2025
- Study start18 Feb 2025
- Primary completionOct 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myopia ProgressingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 91 participants (actual)
Sponsor and investigators
- Lead sponsor
- Essilor International
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Visioncare Research Ltd.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06884527
- Sponsor's protocol ID
- WS10415
- Status last verified
- Sep 2026
- First submitted
- 13 Mar 2025
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Yes: Only IPD used in the results publication will be shared
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Evaluation of A Innovative Spectacle Lens in Slowing Myopia Progression - A Cessation Study
- ClinicalTrials.gov ID
- NCT06884527
- Acronym / sponsor ID
- WS10415
- Conditions
- Myopia Progressing
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 91 participants (actual)
- Lead sponsor
- Essilor InternationalIndustry (pharma, biotech, devices)
- Collaborators
- Visioncare Research Ltd.
- Study start
- 18 Feb 2025 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 19 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to quantify myopic progression following cessation of a innovative spectacle lenses after 3 years' use.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| (Previous Test Group) - Single Vision Spectacle Lens - Innovative Lens | Experimental | Device: Single Vision Lens to A innovative spectacle lens |
| (Previous Control Group) - Single Vision Spectacle Lens - Innovative Lens | Placebo comparator | Device: Single Vision Lens to A innovative spectacle lens |
Who may qualify
- Ages
- 9 to 15 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Existing subjects from the NCT05174780 clinical study.
- Ability to comply with study procedures.
- Informed consent of parent/guardian and assent of subject.
Key exclusion criteria (1 listed)
- Current ocular infection, inflammation, or irritation likely to affect vision.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single Vision Lens to A innovative spectacle lensParticipants in this arm are from the test group of the previous clinical trial (NCT05174780), where they wore the innovative spectacle lenses for three years. They will now wear single vision lenses for 12 months. | Device | (Previous Test Group) - Single Vision Spectacle Lens - Innovative Lens |
| Single Vision Lens to A innovative spectacle lensParticipants in this arm are from the control group of the previous clinical trial (NCT05174780), where they wore the single vision spectacle lenses for three years. They will now wear single vision lenses for another 12 months. | Device | (Previous Control Group) - Single Vision Spectacle Lens - Innovative Lens |
Primary outcome
Change in cycloplegic spherical equivalent refraction from baseline
Time frame: 0 - 12 months
Change in Axial Length from baseline
Time frame: 0 - 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: Yes. Only IPD used in the results publication will be shared
Related trials for Myopia Progressing
RecruitingPhase 2
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Myopia Progressing
Active, not recruitingPhase 3
MAD Trial: Myopia Atropine Dose
Progressive Myopia
Active, not recruitingObservational study
Dynamic Pupil Variations and the Efficacy of Peripheral Defocus Spectacle Lenses in Slowing Myopia Progression
Myopia Progressing
Active, not recruiting
Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial
Myopia, Progressive
Active, not recruiting
Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression
Myopia Progressing, Myopia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Single Vision Lens to A innovative spectacle lens in people with Myopia Progressing, run by Essilor International at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in cycloplegic spherical equivalent refraction from baseline (time frame: 0 - 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.